S. Bruderer

发表

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.

A. Halabi, J. Dingemanse, P. Kaufmann, 2015, British journal of clinical pharmacology.

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

J. Dingemanse, P. Kaufmann, T. Mant, 2015, American Journal of Cardiovascular Drugs.

A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial

J. Dingemanse, A. Krause, D. Baldoni, 2014, Clinical Drug Investigation.

Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex

J. Dingemanse, P. Sidharta, J. Marjason, 2013, Pharmacology.

Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage

J. Zisowsky, J. Dingemanse, A. Krause, 2014, European Journal of Clinical Pharmacology.

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

G. Hopfgartner, M. Seiberling, A. Treiber, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects

D. Csonka, S. Grill, P. Sidharta, 2020, British journal of clinical pharmacology.

Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.

S. Krähenbühl, M. Haschke, J. Dingemanse, 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension

J. Dingemanse, S. Bruderer, N. Hurst, 2017, Expert opinion on drug safety.

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

J. Dingemanse, P. Kaufmann, S. Bruderer, 2014, Pharmacology.

Influence of Severe Renal Impairment on the Pharmacokinetics of Clazosentan

J. Dingemanse, S. Bruderer, B. Sasu, 2011, Journal of clinical pharmacology.

Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects

A. Halabi, J. Dingemanse, S. Bruderer, 2017, British journal of clinical pharmacology.

Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.

J. Dingemanse, S. Bruderer, N. Tsvitbaum, 2011, British journal of clinical pharmacology.

Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag

J. Dingemanse, I. Ulč, S. Bruderer, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension

J. Dingemanse, A. Krause, M. Machacek, 2017, CPT: pharmacometrics & systems pharmacology.

Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects.

J. Dingemanse, T. Mant, S. Bruderer, 2016, Clinical therapeutics.

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

A. Treiber, J. Dingemanse, P. Sidharta, 2011, The AAPS Journal.

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

J. P. Perez Ruixo, I. Poggesi, S. Bruderer, 2020, British journal of clinical pharmacology.

Phosphorylation of splicing factor SF1 on Ser20 by cGMP‐dependent protein kinase regulates spliceosome assembly

P. Milburn, A. Krämer, P. Robinson, 1999, The EMBO journal.

First-in-Humans Study of the Safety, Tolerability, and Pharmacokinetics of ACT-451840, a New Chemical Entity with Antimalarial Activity

R. de Kanter, J. Dingemanse, T. Pfeifer, 2014, Antimicrobial Agents and Chemotherapy.

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist

B. Darpo, J. Dingemanse, P. Kaufmann, 2014, Drug design, development and therapy.

A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects

J. Dingemanse, P. Juif, S. Bruderer, 2017, European Journal of Clinical Pharmacology.

A Microarray-based Detection System for Genetically Modified (GM) Food Ingredients

Patrick Philipp, Marta Hernández, Pere Puigdomènech, 2006, Plant Molecular Biology.

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects

J. Pérez-Ruixo, D. Csonka, R. Štěpánová, 2019, Clinical Drug Investigation.

A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects

J. Dingemanse, P. Juif, S. Bruderer, 2017, European Journal of Clinical Pharmacology.